Zydus Pharmaceuticals M?xico S.a. D Pharmaceutical Import Profile — Mexico (DGFT 2022–2026)

Name: Zydus Pharmaceuticals M?xico S.a. D Pharmaceutical Import Records from India — 2 Products, $300.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Zydus Pharmaceuticals M?xico S.a. D — Pharmaceutical Importer Profile (2026) | 2 Products, $300.0K Trade | TransData Nexus

Zydus Pharmaceuticals M?xico S.a. D — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Zydus Pharmaceuticals México S.A. de C.V. is a subsidiary of Zydus Lifesciences Limited, a fully integrated global healthcare provider headquartered in Ahmedabad, India. Established in Mexico on July 21, 2010, the company commenced its commercial operations in June 2013. Headquartered in Mexico City, Zydus Pharmaceuticals México focuses on importing and distributing a diverse range of pharmaceutical products, with a particular emphasis on oncology treatments.

The company's mission is to create healthier communities by providing high-quality, affordable healthcare solutions. This commitment is reflected in their dedication to innovation and adherence to stringent quality standards. Zydus Pharmaceuticals México operates within Mexico's pharmaceutical distribution network, serving both government and private sectors, and plays a significant role in enhancing access to essential medications across the country.

2Distribution Network

Zydus Pharmaceuticals México S.A. de C.V. is headquartered at Carretera Picacho Ajusco 154-601B, Colonia Jardines en la Montaña, Mexico City, Mexico. While specific details about their warehouse locations and logistics capabilities are not publicly disclosed, the company's strategic position in Mexico City suggests a centralized distribution model. This location likely facilitates efficient access to major transportation routes, enabling effective distribution throughout Mexico and potentially to neighboring regions.

3Industry Role

Zydus Pharmaceuticals México S.A. de C.V. functions primarily as a pharmaceutical importer and distributor within Mexico's supply chain. By sourcing finished pharmaceutical formulations from India, the company ensures the availability of essential medications, particularly in the oncology therapeutic area. Their role is crucial in bridging the gap between international manufacturers and the Mexican market, thereby enhancing the accessibility of critical healthcare products.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Zydus Pharmaceuticals M?xico S.a. D

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

The company's import data indicates a focused sourcing strategy, with a total import value of $300,000 USD from India across six shipments, all comprising finished pharmaceutical formulations in the advanced oncology category. This concentration suggests a strategic choice to specialize in oncology treatments, aligning with market demand and the company's expertise. The consistent sourcing pattern over multiple shipments indicates a stable and reliable relationship with Indian suppliers, reducing potential risks associated with supplier dependency.

2Supply Chain Resilience

Zydus Pharmaceuticals México S.A. de C.V.'s supply chain resilience is supported by its affiliation with Zydus Lifesciences Limited, which has a robust global manufacturing network. This affiliation provides access to multiple suppliers and manufacturing facilities, enhancing the company's ability to mitigate risks associated with single-source dependency. The focus on finished pharmaceutical formulations, particularly in oncology, suggests a strategic emphasis on specialized products, which may require careful management of shipping routes and regulatory compliance. While specific details about backup suppliers and shipping routes are not publicly available, the company's established presence and affiliations likely contribute to a resilient supply chain capable of adapting to market dynamics.

Importing Pharmaceuticals into Mexico — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Mexico

1Regulatory Authority & Framework

In Mexico, the Federal Commission for the Protection against Sanitary Risks (COFEPRIS) is the primary regulatory authority overseeing pharmaceutical imports and marketing authorizations. The regulatory framework governing pharmaceutical imports includes compliance with COFEPRIS regulations, adherence to Good Manufacturing Practices (GMP), and obtaining necessary import licenses. For Indian generics, the marketing authorization pathway involves submitting comprehensive dossiers to COFEPRIS, demonstrating product safety, efficacy, and quality, as well as compliance with labeling and packaging requirements.

2Import Licensing & GMP

Import licensing requirements in Mexico necessitate that pharmaceutical products meet COFEPRIS standards, including GMP certification. Recognized certifications such as EU GMP, WHO GMP, and PIC/S are typically accepted by COFEPRIS, facilitating the import process for manufacturers holding these certifications. Additionally, obtaining wholesale distribution authorization is essential for companies like Zydus Pharmaceuticals México S.A. de C.V. to legally distribute imported pharmaceutical products within Mexico.

3Quality & Labeling

Zydus Pharmaceuticals M?xico S.a. D — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Zydus Pharmaceuticals México S.A. de C.V.'s focus on importing finished pharmaceutical formulations in the advanced oncology category aligns with the growing demand for cancer treatments in Mexico. The decision to concentrate on this therapeutic area is likely driven by the high unmet medical needs and the potential for improving patient outcomes. By specializing in oncology, the company can leverage its expertise and establish a strong presence in a critical segment of the pharmaceutical market.

2Sourcing Profile

The company's sourcing strategy emphasizes importing generic drugs, particularly in the oncology therapeutic area, from India. This approach allows Zydus Pharmaceuticals México S.A. de C.V. to offer cost-effective treatment options while maintaining high-quality standards. India's established reputation in pharmaceutical manufacturing, coupled with recognized GMP certifications, makes it a strategic partner for sourcing these specialized formulations.

3Market Positioning

Based on its product mix, Zydus Pharmaceuticals México S.A. de C.V. serves the hospital and government tender segments of the Mexican market. By focusing on advanced oncology treatments, the company addresses the needs of healthcare institutions requiring specialized medications for cancer care. This positioning enables Zydus Pharmaceuticals México to contribute significantly to the healthcare infrastructure by providing essential therapies to critical care settings.

Seller's Guide — How to Become a Supplier to Zydus Pharmaceuticals M?xico S.a. D

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Zydus Pharmaceuticals México S.A. de C.V., particularly in the oncology therapeutic area. The company's focused sourcing strategy indicates a preference for specialized products, creating a niche for suppliers offering high-quality, cost-effective oncology formulations. Identifying gaps in the current sourcing, such as specific oncology treatments not yet imported, could present avenues for new suppliers to enter the market.

2Requirements & Qualifications

Indian exporters aiming to supply Zydus Pharmaceuticals México S.A. de C.V. must ensure their products comply with COFEPRIS regulations, including holding recognized GMP certifications such as EU GMP, WHO GMP, or PIC/S. Additionally, products must meet labeling requirements in Spanish and adhere to serialization mandates. Establishing a partnership with a reputable distributor like Zydus Pharmaceuticals México S.A. de C.V. requires demonstrating product quality, regulatory compliance, and the ability to meet market demand effectively.

3How to Approach

Frequently Asked Questions — Zydus Pharmaceuticals M?xico S.a. D

What products does Zydus Pharmaceuticals M?xico S.a. D import from India?

Zydus Pharmaceuticals M?xico S.a. D imports 2 pharmaceutical products across 1 categories. Top imports: Bevacizumab ($150.0K), Trastuzumab ($150.0K).

What is Zydus Pharmaceuticals M?xico S.a. D's total pharmaceutical import value?

Zydus Pharmaceuticals M?xico S.a. D's total pharmaceutical import value from India is $300.0K, based on 6 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Zydus Pharmaceuticals M?xico S.a. D focus on?

Zydus Pharmaceuticals M?xico S.a. D imports across 1 categories. The largest: Advanced Oncology (100.0%).

Get Full Zydus Pharmaceuticals M?xico S.a. D Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.

#	Product	Category	Value	Ships	Share	Rk
1	Bevacizumab	Advanced Oncology	$150.0K	3	0.3%	6
2	Trastuzumab	Advanced Oncology	$150.0K	3	0.2%	8

Zydus Pharmaceuticals M?xico S.a. D

Zydus Pharmaceuticals M?xico S.a. D — Import Portfolio & Supplier Network

What Products Does Zydus Pharmaceuticals M?xico S.a. D Import?

Top Products by Import Value

Zydus Pharmaceuticals M?xico S.a. D Therapeutic Categories — 1 Specializations

Import Portfolio — Top 2 by Import Value

Key Metrics

Top Categories

Related Trade Data

Need Detailed Data?